|
N4 Pharma PLC on Friday said its loss narrowed during 2024 on increased research costs, and the firm awaits US approval for the development of a glaucoma therapy. The Derbyshire, England-based pharmaceutical company said its pretax loss narrowed to £1.2 million in 2024 from £1.4 million in 2023. This was largely driven by research and development costs reducing by 37% to £390,387 from £619,392, as well as a one-off £89,175 cost for the purchase of investments in 2023. Revenue multiplied to £7,282 from £1,953, while general and administration costs increased 17% to £837,996 from £717,980. ‘N4 Pharma delivered strong technical and operational progress during the year. The Company has a clear strategic focus on advancing our Nuvec RNA delivery platform. Nuvec continues to generate compelling pre-clinical data and meets key performance criteria needed to address the core challenge in RNA therapeutics - safe and effective delivery,’ said Chief Executive Officer Nigel Theobald. ‘Following our successful fundraising, we have initiated an expanded work programme to strengthen the commercial data package around Nuvec, to secure licensing agreements with third parties. This work is being driven by a high-calibre operational team and will be delivered over the next 12 to 18 months.’ N4 Pharma now awaits the US Food & Drug Administration’s decision on its orphan drug designation application for ECP105, which is used in the treatment of glaucoma to reduce post-surgical scarring without cytotoxic side effects. Obtaining this FDA status is expected to bring ‘substantial’ cost and time savings on development work for ECP105. CEO Theobald continued: ‘Nuvec represents a significant opportunity to create long-term value. We remain committed to unlocking its full commercial potential to deliver shareholder value as we execute our strategy and build momentum.’ Shares in N4 Pharma were up 5.3% at 0.50 pence each in London on Friday morning. The stock remains down 21% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
